Clinical Trial Update: Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating tazemetostat with doxorubicin as frontline therapy for advanced epithelioid sarcoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelioid Sarcoma
• Soft Tissue Sarcoma

Drugs mentioned

• Doxorubicin (doxorubicin)
• TAZVERIK (TAZEMETOSTAT)

Snippet

Sponsor: Epizyme, Inc. | Conditions: Advanced Soft-tissue Sarcoma, Advanced Epithelioid Sarcoma | Phase 1 | Status: TERMINATED